Eli Lilly Acquires Pegilodecakin, Potential Immunotherapy Now in Phase 3 Trial – Immuno-Oncology News
Immuno-Oncology News |
Eli Lilly Acquires Pegilodecakin, Potential Immunotherapy Now in Phase 3 Trial
Immuno-Oncology News Eli Lilly announced that it is acquiring ARMO BioSciences and its lead treatment candidate pegilodecakin (AM0010), an investigational immunotherapy that has shown clinical benefit in multiple types of cancer and is now in a pivotal study in advanced … |
